PL3227325T3 - Selektywne kompozycje inhibitorów trans-sygnałowania il-6 - Google Patents
Selektywne kompozycje inhibitorów trans-sygnałowania il-6Info
- Publication number
- PL3227325T3 PL3227325T3 PL15834723.7T PL15834723T PL3227325T3 PL 3227325 T3 PL3227325 T3 PL 3227325T3 PL 15834723 T PL15834723 T PL 15834723T PL 3227325 T3 PL3227325 T3 PL 3227325T3
- Authority
- PL
- Poland
- Prior art keywords
- trans
- signaling inhibitors
- selective compositions
- selective
- compositions
- Prior art date
Links
- 108090001005 Interleukin-6 Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5412—IL-6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14195726 | 2014-12-01 | ||
| PCT/NL2015/050837 WO2016089206A2 (en) | 2014-12-01 | 2015-12-01 | Selective il-6-trans-signalling inhibitor compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3227325T3 true PL3227325T3 (pl) | 2024-10-07 |
Family
ID=52000745
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15834723.7T PL3227325T3 (pl) | 2014-12-01 | 2015-12-01 | Selektywne kompozycje inhibitorów trans-sygnałowania il-6 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US10519218B2 (pl) |
| EP (2) | EP3227325B1 (pl) |
| JP (2) | JP6827941B2 (pl) |
| KR (2) | KR20240131465A (pl) |
| CN (1) | CN107406491A (pl) |
| CA (1) | CA2969314A1 (pl) |
| DK (1) | DK3227325T3 (pl) |
| ES (1) | ES2981475T3 (pl) |
| FI (1) | FI3227325T3 (pl) |
| HR (1) | HRP20240581T1 (pl) |
| HU (1) | HUE066987T2 (pl) |
| LT (1) | LT3227325T (pl) |
| MA (1) | MA41116B1 (pl) |
| MD (1) | MD3227325T2 (pl) |
| MX (2) | MX388268B (pl) |
| PL (1) | PL3227325T3 (pl) |
| PT (1) | PT3227325T (pl) |
| RS (1) | RS65665B1 (pl) |
| SI (1) | SI3227325T1 (pl) |
| WO (1) | WO2016089206A2 (pl) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS61947B1 (sr) | 2014-12-01 | 2021-07-30 | Ferring Bv | Davanje selektivnog inhibitora il-6-trans-signalizacije |
| EP3227325B1 (en) | 2014-12-01 | 2024-04-10 | Ferring B.V. | Selective il-6-trans-signalling inhibitor compositions |
| CA3080656A1 (en) | 2017-10-30 | 2019-05-09 | Baxalta GmbH | Environmentally compatible detergents for inactivation of lipid-enveloped viruses |
| CA3083971A1 (en) * | 2017-11-30 | 2019-06-06 | Bio-Thera Solutions, Ltd. | Liquid formulation of humanized antibody for treating il-6 related diseases |
| US11845952B2 (en) * | 2018-02-07 | 2023-12-19 | Nippon Medical School Foundation | Adeno-associated virus vector |
| TWI897977B (zh) * | 2020-06-10 | 2025-09-21 | 荷蘭商菲林公司 | 用於治療動脈粥樣硬化性心血管疾病之藥物化合物 |
| WO2022139580A1 (en) | 2020-12-22 | 2022-06-30 | Ferring B.V. | Blood gene expression biomarkers to predict response in patients with inflammatory bowel diseases |
| CN114681592A (zh) * | 2020-12-31 | 2022-07-01 | 天境生物科技(杭州)有限公司 | 包含可溶性gp130二聚体的制剂和使用方法 |
| WO2024011946A1 (en) * | 2022-07-12 | 2024-01-18 | I-Mab Biopharma (Hangzhou) Co., Ltd | Polypeptide dimers for the treatment of systemic sclerosis |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| JPH04218000A (ja) | 1990-02-13 | 1992-08-07 | Kirin Amgen Inc | 修飾ポリペプチド |
| WO1994012520A1 (en) | 1992-11-20 | 1994-06-09 | Enzon, Inc. | Linker for linked fusion polypeptides |
| US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
| US5783672A (en) | 1994-05-26 | 1998-07-21 | Immunex Corporation | Receptor for oncostatin M |
| US6472179B2 (en) | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
| DE19941897B4 (de) | 1999-09-02 | 2006-06-14 | GSF - Forschungszentrum für Umwelt und Gesundheit GmbH | IL-6 Rezeptor-Protein, Beta-Kette (gp130) des IL-6 Rezeptor-Proteins, für diese Proteine kodierende DNA, davon abgeleitete RNA, Peptid mit den Aminosäuren 771-811 dieser Beta-Kette oder Teilen davon und deren Verwendungen |
| ATE336514T1 (de) | 2000-02-11 | 2006-09-15 | Merck Patent Gmbh | Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen |
| ES2298106T3 (es) | 2000-04-21 | 2008-05-16 | Conaris Research Institute Ag | Proteinas de fusion que comprenden dos moleculas gp130 solubles. |
| MY137181A (en) | 2001-05-21 | 2009-01-30 | Nektar Therapeutics | Pulmonary administration of chemically modified insulin |
| WO2003008454A2 (en) | 2001-07-18 | 2003-01-30 | Merck Patent Gmbh | Glycoprotein vi fusion proteins |
| AU2002356511A1 (en) | 2001-07-30 | 2003-04-01 | Immunex Corporation | T. reesei phytase enyzmes, polynucleides encoding the enzymes, vectors and host cells thereof, and methods of using |
| JP2004182638A (ja) | 2002-12-03 | 2004-07-02 | Yakult Honsha Co Ltd | 炎症性疾患又は悪性腫瘍の予防治療剤 |
| EP1491554A1 (en) | 2003-06-23 | 2004-12-29 | CONARIS research institute AG | PEGylated soluble gp130-dimers useful as a medicament |
| ATE399868T1 (de) | 2004-08-27 | 2008-07-15 | Conaris Res Inst Ag | Optimierte nukleotidsequenzen die für sgp130 kodieren |
| EP1801121A1 (en) | 2005-12-23 | 2007-06-27 | CONARIS research institute AG | Soluble gp130 molecule variants useful as a medicament |
| EP1966244B1 (en) * | 2005-12-30 | 2012-03-21 | Merck Patent GmbH | Anti-il-6 antibodies preventing the binding of il-6 complexed with il-6ralpha to gp130 |
| ES2352561T3 (es) * | 2006-06-30 | 2011-02-21 | Conaris Research Institute Ag | Dímeros de sgp 130fc mejorados. |
| KR20140107702A (ko) * | 2006-06-30 | 2014-09-04 | 코나리스 리써치 인스티튜트 아게 | 개선된 ｓｇｐ130Ｆｃ 이량체 |
| EP2050759A1 (en) * | 2007-10-19 | 2009-04-22 | CONARIS research institute AG | Soluble gp 130 muteins with improved binding activity |
| CN107267459A (zh) * | 2011-01-06 | 2017-10-20 | 约翰·霍普金斯大学 | 在哺乳动物细胞中产生具有延长的循环半衰期的重组糖蛋白的方法 |
| RS61947B1 (sr) * | 2014-12-01 | 2021-07-30 | Ferring Bv | Davanje selektivnog inhibitora il-6-trans-signalizacije |
| EP3227325B1 (en) | 2014-12-01 | 2024-04-10 | Ferring B.V. | Selective il-6-trans-signalling inhibitor compositions |
-
2015
- 2015-12-01 EP EP15834723.7A patent/EP3227325B1/en active Active
- 2015-12-01 ES ES15834723T patent/ES2981475T3/es active Active
- 2015-12-01 US US15/532,097 patent/US10519218B2/en active Active
- 2015-12-01 MD MDE20170158T patent/MD3227325T2/ro unknown
- 2015-12-01 KR KR1020247027872A patent/KR20240131465A/ko active Pending
- 2015-12-01 EP EP24154182.0A patent/EP4356962A3/en active Pending
- 2015-12-01 MA MA41116A patent/MA41116B1/fr unknown
- 2015-12-01 PT PT158347237T patent/PT3227325T/pt unknown
- 2015-12-01 HR HRP20240581TT patent/HRP20240581T1/hr unknown
- 2015-12-01 KR KR1020177018154A patent/KR102699098B1/ko active Active
- 2015-12-01 FI FIEP15834723.7T patent/FI3227325T3/fi active
- 2015-12-01 HU HUE15834723A patent/HUE066987T2/hu unknown
- 2015-12-01 RS RS20240718A patent/RS65665B1/sr unknown
- 2015-12-01 SI SI201532012T patent/SI3227325T1/sl unknown
- 2015-12-01 CA CA2969314A patent/CA2969314A1/en active Pending
- 2015-12-01 LT LTEPPCT/NL2015/050837T patent/LT3227325T/lt unknown
- 2015-12-01 DK DK15834723.7T patent/DK3227325T3/da active
- 2015-12-01 WO PCT/NL2015/050837 patent/WO2016089206A2/en not_active Ceased
- 2015-12-01 JP JP2017547367A patent/JP6827941B2/ja active Active
- 2015-12-01 CN CN201580075068.9A patent/CN107406491A/zh active Pending
- 2015-12-01 PL PL15834723.7T patent/PL3227325T3/pl unknown
- 2015-12-01 MX MX2017007069A patent/MX388268B/es unknown
-
2017
- 2017-06-05 MX MX2021007899A patent/MX2021007899A/es unknown
-
2019
- 2019-11-06 US US16/675,621 patent/US11306136B2/en active Active
-
2021
- 2021-01-20 JP JP2021007075A patent/JP7184936B2/ja active Active
-
2022
- 2022-03-09 US US17/690,711 patent/US20220275056A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL281638B1 (en) | Angiotensinogen (agt) irna compositions and methods of use thereof | |
| IL263586B (en) | Inhibitors of the menin-mll interaction | |
| DK3102576T3 (da) | Dihydropyrrolopyridininhibitorer af ror-gamma | |
| LT3303334T (lt) | Tirozinkinazės inhibitoriai | |
| HUE042335T2 (hu) | ROR-gamma dihidropirrolopiridin inhibitorai | |
| EP3377059A4 (en) | INHIBITORS OF CXCR2 | |
| DK3164380T3 (da) | Hæmmere af lysinspecifik demethylase-1 | |
| LT3137169T (lt) | Lizinui specifinės demetilazės-1 inhibitoriai | |
| DK3160956T3 (da) | Inhibitorer af lysin-specifik demethylase-1 | |
| DK3442972T3 (da) | Bromdomænehæmmere | |
| DK3144001T3 (da) | Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf | |
| LT3191487T (lt) | Katepsino c spirocikliniai inhibitoriai | |
| DK3215173T3 (da) | Glycopeptidsammensætninger | |
| DK3341379T3 (da) | EZH2-hæmmere | |
| DK3116475T3 (da) | Dopa-decarboxylasehæmmersammensætninger | |
| PL3227325T3 (pl) | Selektywne kompozycje inhibitorów trans-sygnałowania il-6 | |
| DK3186242T3 (da) | Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere | |
| LT3288944T (lt) | Imidazopirazinonai, kaip pde1 inhibitoriai | |
| DK3132009T3 (da) | Fremgangsmåde | |
| DK3283210T3 (da) | Fremgangsmåde | |
| DK3114120T3 (da) | Tetrazolon-substituerede dihydropyridinon-mgat2-hæmmere | |
| DK3240767T3 (da) | Mikroindkapslede nitrifikationshæmmersammensætninger | |
| DK3204352T3 (da) | Hæmmere af lysin-gingipain | |
| HRP20181441T1 (hr) | Inhibitori sintaze aldosterona | |
| IL254502B (en) | Solid forms of menaquinols |